An Bin Hu
Sun Yat-sen University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by An Bin Hu.
Journal of Digestive Diseases | 2013
Xiao Yan Wang; Dong Chen; Xiang Song Zhang; Zhi Feng Chen; An Bin Hu
To evaluate the role of positron emission tomography/computer tomography with fluorine‐18 fluorodeoxyglucose (18F‐FDG‐PET/CT) in detecting hepatocellular carcinoma (HCC) recurrence after hepatectomy and/or radiofrequency ablation (RFA) and to compare its efficacy with contrast‐enhanced ultrasound (CEUS).
Journal of Digestive Diseases | 2013
An Bin Hu; Lin Wei Wu; Qiang Tai; Xiao Feng Zhu; Xiao Shun He
To evaluate the safety and efficacy of steroid‐minimization therapy in liver transplantation (LT) recipients with hepatitis B virus‐related diseases in China.
Hepatobiliary & Pancreatic Diseases International | 2014
Ming Han; Zhi Yong Guo; Qiang Zhao; Xiaoping Wang; Xiao Peng Yuan; Xing Yuan Jiao; Chun Hua Yang; Dongping Wang; Wei Qiang Ju; Lin Wei Wu; An Bin Hu; Qiang Tai; Yi Ma; Xiao Feng Zhu; Xiao Shun He
BACKGROUND In 2011, a pilot program for deceased organ donation was initiated in China. We describe the first successful series of liver transplants in the pilot program. METHODS From July 2011 to August 2012, our center performed 26 liver transplants from a pool of 29 deceased donors. All organ donation and allograft procurement were conducted according to the national protocol. The clinical data of donors and recipients were collected and summarized retrospectively. RESULTS Among the 29 donors, 24 were China Category II donors (organ donation after cardiac death), and five were China Category III donors (organ donation after brain death followed by cardiac death). The recipients were mainly the patients with hepatocellular carcinoma. The one-year patient survival rate was 80.8% with a median follow-up of 422 (2-696) days. Among the five mortalities during the follow-up, three died of tumor recurrence. In terms of post-transplant complications, 9 recipients (34.6%) experienced early allograft dysfunction, 1 (3.8%) had non-anastomotic biliary stricture, and 1 (3.8%) was complicated with hepatic arterial thrombosis. None of these complications resulted in patient death. Notably, primary non-function was not observed in any of the grafts. CONCLUSION With careful donor selection, liver transplant from deceased donors can be performed safely and plays a critical role in overcoming the extreme organ shortage in China.
Hepatobiliary & Pancreatic Diseases International | 2012
Lin Wei Wu; Zhi Yong Guo; Qiang Tai; Wei Qiang Ju; Dongping Wang; An Bin Hu; Xiao Feng Zhu; Xiao Shun He
BACKGROUND Steroids have been the mainstay of immunosuppressive regimen in liver transplantation. However, the use of steroids is associated with various post-transplant complications. This study evaluated the efficacy and safety of reduced immunosuppressive regimen with steroids (steroid elimination within 24 hours post-transplant) in a cohort of Chinese liver transplant recipients. METHODS Seventy-six patients in line with the selection criteria were enrolled in this prospective study. All patients received anti-IL-2 receptor antibody induction and tacrolimus-based maintenance therapy. The recipients were divided into two groups according to the duration of steroid use: 40 transplant in a 3-month withdrawal group and the remaining 36 in a 24-hour elimination group. Recipient survival, post-operative infections, biopsy-proven acute rejection and steroid-resistant acute rejection, non-healing wound, recurrence of hepatitis B virus (HBV) and hepatocellular carcinoma (HCC), de novo diabetes, hyperlipidemia and hypertension were assessed in the two groups. RESULTS There was no significant difference in patient survival, incidence of acute rejection episodes and hyperlipidemia, and recurrence of HBV and HCC between the two groups. However, the incidence rates of post-transplant infection, non-healing wound, de novo diabetes and hypertension were significantly lower in the 24-hour elimination group than in the 3-month withdrawal group (all P values <0.05). CONCLUSION Under anti-IL-2 receptor antibody induction and tacrolimus-based maintainance, steroid elimination within 24 hours post-transplant is associated with reduced steroid-related complications without increasing the risk of rejection.
Liver Transplantation | 2017
Xiao Shun He; Shun Jun Fu; Qiang Zhao; Xiao Feng Zhu; Dongping Wang; Ming Han; Wei Qiang Ju; Yi Ma; Xing Yuan Jiao; Xiao Peng Yuan; An Bin Hu; Zhi Yong Guo
In liver transplant patients with type 2 diabetes mellitus (DM), the disease worsens after transplantation because of longterm use of diabetogenic immunosuppressive drugs, making management of those patients a great challenge. The objective of our study was to evaluate the safety and efficacy of a simplified multivisceral transplantation (SMT) procedure for the treatment of patients with end‐stage liver disease and concurrent type 2 DM. Forty‐four patients who had pretransplant type 2 DM were included. A total of 23 patients received SMT, and 21 patients received orthotopic liver transplantation (OLT). Patient and graft survivals, complications, diabetic control, and quality of life (QOL) were retrospectively analyzed in both groups. The 1‐, 3‐, and 5‐year cumulative patient and graft survival rates were 91.5%, 75.4%, and 75.4% in the SMT group and were 94.4%, 64.4%, and 64.4% in the OLT group, respectively (P = 0.70). Interestingly, 95.7% (22/23) of patients achieved complete remission from DM after SMT compared with 16.7% (3/18) of patients after OLT. The occurrence of biliary complication was significantly higher in the OLT group than that in the SMT group (23.8% versus 0.0%; P = 0.01). Moreover, better QOL was observed in the SMT group than that in the OLT group. In conclusion, the SMT procedure we described here is a safe and viable option for patients with end‐stage live disease and concurrent type 2 DM. This SMT procedure offers excellent transplant outcomes and QOL. Liver Transplantation 23 1161–1170 2017 AASLD.
Experimental and Clinical Transplantation | 2012
Wei Qiang Ju; Zhi Yong Guo; Xiaoting Ling; Xiao Shun He; Lin Wei Wu; Qiang Tai; An Bin Hu; Ming Han; Xiao Feng Zhu
Experimental and Clinical Transplantation | 2012
Wei Qiang Ju; Zhi Yong Guo; Wen Hua Liang; Lin Wei Wu; Qiang Tai; An Bin Hu; Ming Han; Xiao Feng Zhu; Xiaoshun He
Chinese journal of surgery | 2008
You S; Xiao Shun He; An Bin Hu; Xiong J; Lin Wei Wu; Dongping Wang; Guo Dong Wang; Yi Ma; Wei Qiang Ju; Jie Fu Huang
Chinese journal of surgery | 2008
An Bin Hu; Xiao Shun He; Zhi peng Wu; Xiao Feng Zhu; Yi Ma; Dongping Wang; Guo Dong Wang; Qiang Tai; Wei Qiang Ju; Lin Wei Wu; Jie Fu Huang
Chinese journal of surgery | 2008
Yi Ma; Xiao Shun He; Xiao Feng Zhu; Guo Dong Wang; Dongping Wang; Wei Qiang Ju; Lin Wei Wu; An Bin Hu; Qiang Tai